7 9
J U LY 2 0 1 4 | O U T P AT I E N T S U R G E R Y M A G A Z I N E O N L I N E
ized delivery device, which precisely and permanently changes the
shape of the implanted lens. With this technology, it's quite possible
we'll be able to hit the bull's-eye of 20/20 vision every time.
6. Imprimis Pharmaceuticals /
Dropless cataract surgery
After surgery, we prescribe eyedrops: antibiotic, steroidal and non-
steroidal drugs to be administered 3 times a day for up to 3 weeks. This
can be an inconvenience for patients — if they carry out our post-op
instructions — and expensive as well. Imprimis Pharmaceuticals prom-
ises to prevent post-op infection and inflammation droplessly, with a sin-
gle injection. Their proprietary sterile formulations compound a steroid
and antibiotics for intraoperative injection into the vitreous, where the
"depot effect" delivers them over time. This changes the game! A single-
use, 2ml vial of Tri-Moxi lists for $20 and a single-use, 1ml vial of Tri-
Moxi-Vanc is $25.
O P H T H A L M O L O G Y
and capsular bag polishing. Existing Haag-Streit microscopes can be
retrospectively upgraded with the red reflex improvements.
• Omeros Corporation
's Omidria (phenylephrine and ketorolac injection)
1% / 0.3% has received FDA approval for use during cataract surgery
and IOL replacement. The drug, developed for administration through
ocular irrigating solution, prevents intraoperative pupil constriction
while also serving as an anti-inflammatory agent, the only product to
do so. The company anticipates a late summer or early fall U.S.
product launch.
— David Bernard
OSE_1407_part2_Layout 1 7/3/14 8:49 AM Page 79
